IL18 Gene Variants Influence the Susceptibility to Chagas Disease

Daniel A Leon Rodriguez1, F David Carmona1, Luis Eduardo Echeverría2

  • 1Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, P.T.S., Granada, Spain.

Insights

Genetic variations in the Interleukin 18 (IL18) gene promoter influence susceptibility to Trypanosoma cruzi infection, the parasite causing Chagas disease. However, these IL18 variants do not appear to affect the development of chronic Chagas cardiomyopathy (CCC).

Area of Science:

  • Genetics
  • Immunology
  • Infectious Diseases

Background:

  • Chagas disease, caused by Trypanosoma cruzi, affects millions globally.
  • Genetic predisposition may influence Chagas disease severity, including chronic Chagas cardiomyopathy (CCC).
  • Interleukin 18 (IL18), a pro-inflammatory cytokine, is implicated in controlling T. cruzi infection.

Purpose of the Study:

  • To investigate the association of six IL18 gene variants with susceptibility to T. cruzi infection and CCC development.
  • To identify specific IL18 polymorphisms influencing Chagas disease outcomes in a Colombian endemic region.

Main Methods:

  • Genotyping of 1,171 individuals (seronegative, seropositive asymptomatic, CCC) using TaqMan probes for six IL18 variants.
  • Statistical analysis to assess associations between IL18 polymorphisms and T. cruzi infection or CCC.

Main Results:

  • Significant associations were found between T. cruzi infection and IL18 variants rs187238, rs360719, rs2043055, and rs1946518.
  • The strongest association with infection susceptibility was driven by the rs360719 polymorphism in the IL18 promoter region.
  • No significant association was observed between any analyzed IL18 polymorphisms and the development of CCC.

Conclusions:

  • Genetic variation in the IL18 promoter region, particularly rs360719, plays a role in susceptibility to T. cruzi infection.
  • These findings offer new insights into Chagas disease pathophysiology.
  • Targeting IL18 genetic factors may present novel strategies for Chagas disease control.

Related Concept Videos

Exon Recombination02:32

Exon Recombination

The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.3K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
66
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
32.3K